Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

OP011: Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY studyECCO '17 Barcelona
Year: 2017
Authors:

Peyrin-Biroulet L.*1, Feagan B.G.2, Mansfield J.3, Rubin D.T.4, Arulmani U.5, Maciuca R.5, Tyrrell H.6, Thommes J.5, Tole S.6

1Université de Lorraine, Vandœuvre-lès-Nancy, France 2University of Western Ontario, London, Canada 3Newcastle University, Newcastle upon Tyne, United Kingdom 4University of Chicago Medicine, Chicago, United States 5Genentech, South San Francisco, United States 6Roche, Welwyn Garden City, United Kingdom

OP012: Perioperative use of vedolizumab is not associated with short-term postoperative infectious complications in patients with ulcerative colitis undergoing (procto)colectomy with ileal pouch-anal anastomosisECCO '17 Barcelona
Year: 2017
Authors:

Ferrante M.*1, Schils N.1, De Buck van Overstraeten A.2, Vermeire S.1, Van Assche G.1, Wolthuis A.2, D'Hoore A.2

1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium 2University Hospitals Leuven, Department of Abdominal Surgery, Leuven, Belgium

OP013: Disease management and outcomes of patients with Crohn's disease at high risk of recurrence. Results from PRACTICROHN studyECCO '17 Barcelona
Year: 2017
Authors:

Iborra M.*1, Martín Arranz M.D.2, Domènech E.3, García V.4, Gutiérrez A.5, Barreiro-de Acosta M.6, Cea-Calvo L.7, Romero C.7, Juliá B.7

1Servicio de Gastroenterologia, Hospital La Fe, Valencia, Spain 2Hospital Universitario La Paz, Gastroenterology Unit, Madrid, Spain 3Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Badalona, Spain 4Hospital Universitario Reina Sofia, Unidad Clinica de Aparato Digestivo, Cordoba, Spain 5Hospital General Universitario Alicante, Gastroenterology unit, Alicante, Spain 6Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain 7MSD Spain, Medical Department, Madrid, Spain

OP014: Histological remission is predictive of improved clinical outcomes in patients with ulcerative colitis: results from the TOUCHSTONE open-label extensionECCO '17 Barcelona
Year: 2017
Authors:

Sandborn W.1, Feagan B.*2, D'Haens G.3, Levesque B.2, Pai R.4, Hanauer S.5, Wolf D.6, Vermeire S.7, Ghosh S.8, Li C.9, Penenberg D.9, Aranda R.9, Olson A.9

1University of California San Diego, San Diego, United States 2Robarts Research, London, Canada 3Academic Medical Center, Amsterdam, Netherlands 4Mayo Clinic, Department of Laboratory Medicine and Pathology, Scottsdale, United States 5Feinberg School of Medicine, Chicago, United States 6Atlanta Gastroenterology Associates, Atlanta, United States 7University of Leuven, Leuven, Belgium 8University of Calgary, Calgary, Canada 9Receptos, a wholly owned subsidiary of Celgene, San Diego, United States

OP015: Cost-effectiveness of laparoscopic ileocecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C TRIALECCO '17 Barcelona
Year: 2017
Authors:

de Groof J.*1,2, Bemelman W.1, Eshuis E.2, Gardenbroek T.1, Bossuyt P.3, Bosmans J.4, van Dongen H.4, van Wagensveld B.5, Brink M.6, Consten E.7, Buskens C.1, D'Haens G.2, Stokkers P.8, Ponsioen C.2 LIR!C Study Group

1Academic Medical Center, Surgery, Amsterdam, Netherlands 2Academic Medical Center, Gastroenterology, Amsterdam, Netherlands 3Academic Medical Center, Epidemiology, Amsterdam, Netherlands 4VU, Health Sciences, Amsterdam, Netherlands 5OLVG West, Surgery, Amsterdam, Netherlands 6Meander Medical Center, Gastroenterology, Amersfoort, Netherlands 7Meander Medical Center, Surgery, Amersfoort, Netherlands 8OLVG West, Gastroenterology, Amsterdam, Netherlands

OP016: Potential role of bile acid receptor FXR in microscopic colitisECCO '17 Barcelona
Year: 2017
Authors:

Palmela C.*1, Torres J.1, Gomes de Sena P.2, Costa Santos M.P.1, Gouveia C.1, Oliveira M.H.2, Rodrigues C.M.P.3, Cravo M.1, Borralho P.4,5

1Hospital Beatriz Ângelo, Gastrenterology Department, Loures, Portugal 2Hospital Beatriz Ângelo, Pathology Department, Loures, Portugal 3Faculty of Pharmacy, Universidade de Lisboa, Research Institute for Medicines, Lisboa, Portugal 4Hospital Cuf Descobertas, Pathology Department, Lisboa, Portugal 5Universidade de Lisboa, Faculty of Medicine, Lisboa, Portugal

OP017: Telemedicine enables a safe shift from examination room based care to personalised care for inflammatory bowel disease: a pragmatic randomised multicenter trial with myIBDcoachECCO '17 Barcelona
Year: 2017
Authors:

de Jong M.*1,2, van der Meulen-de Jong A.3, Romberg-Camps M.4, Becx M.5, Cilissen M.1, Maljaars J.3, van Bodegraven A.4, Mahmmod N.5, Markus T.6, Hameeteman W.1, Dijkstra G.7, Masclee A.1,2, Boonen A.8,9, Jonkers D.1,2, van Tubergen A.8,9, Pierik M.1,2

1Maastricht University Medical Center (MUMC), Department of Internal Medicine, division of Gastroenterology and Hepatology, Maastricht, Netherlands 2Maastricht University Medical Center (MUMC), NUTRIM – School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands 3Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands 4Zuyderland Medical Centre, Department of Gastroenterology and Hepatology, Sittard-Geleen, Netherlands 5St. Antonius Hospital, Department of Gastroenterology and Hepatology, Nieuwegein, Netherlands 6CCUVN, Woerden, Netherlands 7University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands 8Maastricht University Medical Center (MUMC), Department of Internal Medicine, division of Rheumatology, Maastricht, Netherlands 9Maastricht University Medical Center (MUMC), CAPHRI - School for Public Health and Primary Care, Maastricht, Netherlands

OP018: Optimal anti-TNF stop week during pregnancy depends on anti-TNF typeECCO '17 Barcelona
Year: 2017
Authors:

Kanis S., de Lima A., van der Woude C.

Erasmus University Medical Center, Gastroenterology and Hepatology, Rotterdam, Netherlands

OP019: Correlation of clinical and endoscopic outcomes in patients with active Crohn's disease treated with mongersen (GED-0301)ECCO '17 Barcelona
Year: 2017
Authors:

Feagan B.*1, Colombel J.-F.2, Rossiter G.3, Li X.3, Usiskin K.3, Zhan X.3, Sands B.2

1Robarts Clinical Trials and University of Western Ontario, London, Canada 2Icahn School of Medicine at Mount Sinai, New York, United States 3Celgene Corporation, Summit, United States

OP020: Recent anti-TNF exposure predicts lower vedolizumab trough concentrations in patients with Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Gils A.*1, Dreesen E.1, Compernolle G.1, Peeters M.1, Brouwers E.1, Tops S.1, Ballet V.2, Noman M.2, Ferrante M.2, Van Assche G.2, Vermeire S.2

1KU Leuven, P.O. Box 820 Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium 2UZ Leuven, Campus Gasthuisberg, Department of Gastroenterology and Hepatology, Leuven, Belgium

OP021: Hyperbaric oxygen therapy is safe and effective for hospitalized ulcerative colitis patients suffering from moderate-severe flares: a multi-center, randomized, double-blind, sham-controlled trialECCO '17 Barcelona
Year: 2017
Authors:

Dulai P.*1,2, Buckey Jr. J.2, Raffals L.3, Swoger J.4, Claus P.3, O'Toole K.4, Ptak J.2, Gleeson M.2, Widjaja C.1, Adler J.2, Patel N.2, Skinner L.2, Haren S.3, Goldby-Reffner K.4, Thompson K.2, Knight R.1, Chang J.1, Siegel C.2

1University of California San Diego, La Jolla, CA, United States 2Dartmouth Hitchcock Medical Center, Lebanon, NH, United States 3Mayo Clinic, Rochester, MN, United States 4University of Pittsburgh Medical Center, Pittsburgh, PA, United States

OP022: Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in inflammatory bowel diseases: IBD Character studyECCO '17 Barcelona
Year: 2017
Authors:

Kalla R.*1, Adams A.1, Vatn S.2, Bergemalm D.3, Ricanek P.4, Lindstrom J.2, Ocklind A.5, Nordberg N.5, Kennedy N.1, Ventham N.1, Vatn M.4, Söderholm J.6, Pierik M.7, Törkvist L.8, Gomollόn F.9, Jahnsen J.2, Halfvarson J.3, Satsangi J.1 IBD Character Consortium, Edinburgh, United Kingdom

1University of Edinburgh, Gastroenterology, Edinburgh, United Kingdom 2Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway 3Örebro University, Department of Gastroenterology, Faculty of Medicine and Health, Örebro, Sweden 4University of Oslo, Institute of Clinical Medicine, Oslo, Norway 5Olink Proteomics, Uppsala, Sweden 6Linköping University, Gastroenterology, Linköping, Sweden 7Maastricht University Medical Center (MUMC), Department of Gastroenterology and Hepatology, Maastricht, Netherlands 8Karolinska Instituet, Department of Clinical Science, Intervention and Technology, Karolinska, Sweden 9HCU “Lozano Blesa”, IIS Aragόn, CIBEREHD, Zaragosa, Spain

OP023: Maintenance of clinical effect in patients with moderate-to-severe Crohn's disease treated with filgotinib, a selective JAK1 inhibitor: exploratory 20-week data analysis of the phase 2 FITZROY studyECCO '17 Barcelona
Year: 2017
Authors:

Vermeire S.*1, Schreiber S.2, Petryka R.3, Kuehbacher T.4, Hebuterne X.5, Roblin X.6, Klopocka M.7, Goldis A.8, Wisniewska-Jarosinska M.9, Baranovsky A.10, Sike R.11, Stoyanova K.12, Meuleners L.13, Tasset C.13, Van der Aa A.13, Harrison P.13

1University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium 2University Medical Center Schleswig-Holstein Kiel, Department of Internal Medicine I, Kiel, Germany 3Vivamed, Warsaw, Poland 4Asklepios Hospital West Hamburg, Department of Gastroenterology, Hamburg, Germany 5CHU Nice Hopital l'Archet, Department of Gastroenterology and Nutrition, Nice Cedex 3, France 6North Hospital, Department of Gastroenterology, Saint Priez en Jarez, France 7NC University in Toruń, Collegium Medicum, Bydgoszcz, Poland 8Dr. Goldis Center for Gastroenterology, Ltd., Timisoara, Romania 9Santa LLC, Santa Familia Research, Prevention and Treatment Centre, Lodz, Poland 10City Clinical Hospital #31, St. Petersburg, Russian Federation 11Szent Margit Hospital, Budapest, Hungary 12PSI Pharma Support EOOD, Sofia, Bulgaria 13Galapagos NV, Mechelen, Belgium

OP024: Childhood-onset inflammatory bowel disease and risk of cancer – a Swedish nationwide cohort study 1964–2014ECCO '17 Barcelona
Year: 2017
Authors:

Olén O.*1,2, Askling J.1, Frumento P.3, Sachs M.C.3, Neovius M.1, Eriksson J.1, Smedby K.E.1, Ekbom A.1, Malmborg P.1,2, Ludvigsson J.F.4,5,6,7

1Karolinska Institutet, Department of Medicine Solna, Clinical Epidemiology Unit, Stockholm, Sweden 2Sachs' Children's Hospital, Department of Pediatric Gastroenterology and Nutrition, Stockholm, Sweden 3Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden 4Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden 5Orebro University Hospital, Department of pediatrics, Orebro, Sweden 6University of Nottingham, Division of Epidemiology and Public Health, School of Medicine, Nottingham, United Kingdom 7Columbia University College of Physicians and Surgeons, Department of Medicine, New York, Sweden

OP025: Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naïve pediatric patients with Crohn's disease in clinical practiceECCO '17 Barcelona
Year: 2017
Authors:

Steiner S.*1, King E.2, Park K.3, Pashankar D.4, Shashidhar H.5, Sudel B.6, Eichner S.7, Chen S.2, Pratt J.2, Colletti R.8 ImproveCareNow Network, Burlington, United States

1Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, United States 2Cincinnati Children's Hospital Medical Center, Cincinnati, United States 3Lucile Salter Packard Children's Hospital, Stanford University, Palo Alto, United States 4Yale-New Haven Children's Hospital, New Haven, United States 5New Hampshire's Hospital for Children, Manchester, United States 6University of Minnesota Masonic Children's Hospital, Minneapolis, United States 7AbbVie, North Chicago, United States 8University of Vermont Childen's Hospital, Burlington, United States

OP026: Zero diagnostic yield of dysplasia in polyp adjacent biopsies for patients with inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Lahiff C.*1, Wang L.M.2, Travis S.P.L.1, East J.E.1

1Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Translational Gastroenterology Unit, Experimental Medicine Division, Oxford, United Kingdom 2John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Department of Cellular Pathology, Oxford, United Kingdom

OP027: IL-33/ST2 axis sustains gut mucosal wound healing and cancerogenesis in colitis-associated colorectal cancerECCO '17 Barcelona
Year: 2017
Authors:

Lopetuso L.R.*1,2, De Salvo C.3, Di Martino L.3, Goodman W.3, Scaldaferri F.4, Gasbarrini A.4, Pizarro T.T.3

1Catholic University of the Sacread Hearth, Internal Medicine, Gastroenterology Division, Rome, Italy 2Case Western Reserve University, Pathology, Cleveland, United States 3Case Western Reserve University, Pathology, Cleveland, United States 4Catholic University of Sacred Heart, Internal Medicine Department, Gastroenterology Division, Rome, Italy

OP028: Gut specific regulatory T cells – a new frontier for Crohn's disease therapyECCO '17 Barcelona
Year: 2017
Authors:

Goldberg R.*1,2,3,4, Scotta C.3,4,5, Cooper D.6, Eliraz E.7, Nir E.7, Irving P.1,8, Sanderson J.1,8, Shpigel N.7, Marelli-Berg F.6, Lombardi G.3,4,5, Lord G.2,3,4

1Guy's and St Thomas' NHS Trust, Gastroenterology, London, United Kingdom 2King's College London, Experimental Immunobiology, London, United Kingdom 3King's College London, Medical Research Council Centre for Transplantation, London, United Kingdom 4Guy's and St Thomas' NHS Trust, National Institute for Health Research Biomedical Research Centre, London, United Kingdom 5King's College London, Immunoregulation and Immune Intervention, London, United Kingdom 6Bart's and the London Queen Mary School of Medicine and Dentistry, William Harvey Research Institute, London, United Kingdom 7Hebrew University of Jerusalem, Koret School of Veterinary Medicine, Rehovot, Israel 8King's College London, Diabetes and Nutritional Sciences, London, United Kingdom

OP029: Hypoacetylation of histone-3 is a hallmark of intestinal fibrosis in Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Lewis A.*1, Felice C.1,2, Nihjuis A.1, Iqbal S.1, Mehta S.1, Feakins R.3, Armuzzi A.2, Silver A.1, Lindsay J.4

1Queen Mary's University London, Centre for Genomics and Child Health, Blizard Institute, London, United Kingdom 2Gemelli Hospital Catholic University Foundation, IBD Unit, Presidio Columbus, Rome, Italy 3The Royal London Hospital, Department of pathology, London, United Kingdom 4Queen Mary's University London, Centre for Immunobiology, Blizard Institute, London, United Kingdom

OP030: Identification of disease-relevant bacterial signatures in gnotobiotic IL-10 deficient mice using fecal samples from IBD patients undergoing hematopoietic stem cell transplantationECCO '17 Barcelona
Year: 2017
Authors:

Metwaly A.*1, Butt L.F.1, Waldschmitt N.1, Lagkouvardos I.2, Corraliza A.M.3, Mayorgas A.3, Martinez-Medina M.4, Allez M.5, Panes J.3, Salas A.3, Haller D.1,2

1Technical University Munich, Chair of Nutrition and Immunology, Freising, Germany 2ZIEL-Institute for Food and Health, Technical University of Munich, Freising, Germany 3Instituto de Investigaciones Biomédicas de Barcelona CSIC, IDIBAPS, CIBERehd, Department of Experimental Pathology, Barcelona, Spain 4Laboratory of Molecular Microbiology, Universitat de Girona, Biology Department, Girona, Spain 5APHP, Hôpital Saint Louis, INSERM UMRS 1160, Paris Diderot, Sorbonne Paris-Cité University, Department of Gastroenterology, Paris, France